Literature DB >> 17013842

Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.

Fabrizio Cantini1, Laura Niccoli, Maurizio Benucci, Daniela Chindamo, Carlotta Nannini, Ignazio Olivieri, Angela Padula, Carlo Salvarani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17013842     DOI： 10.1002/art.22236

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  11 in total

1.  Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Authors:  Martin Rudwaleit; Filip Van den Bosch; Martina Kron; Sonja Kary; Hartmut Kupper
Journal:  Arthritis Res Ther       Date:  2010-06-16       Impact factor: 5.156

2.  Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.

Authors:  Fabrizio Conti; Fulvia Ceccarelli; Elisa Marocchi; Leonardo Magrini; Francesca Romana Spinelli; Antonio Spadaro; Rossana Scrivo; Guido Valesini
Journal:  Ann Rheum Dis       Date:  2007-07-05       Impact factor: 19.103

3.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

4.  Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.

Authors:  Marta Fabbroni; Luca Cantarini; Francesco Caso; Luisa Costa; Veronica Anna Pagano; Bruno Frediani; Stefania Manganelli; Mauro Galeazzi
Journal:  Mediators Inflamm       Date:  2014-07-08       Impact factor: 4.711

Review 5.  Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

Authors:  Fabrizio Cantini; Carlotta Nannini; Laura Niccoli
Journal:  Open Access Rheumatol       Date:  2009-12-04

6.  Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis.

Authors:  Stefano Gentileschi; Donato Rigante; Jurgen Sota; Giuseppe Lopalco; Maria Grazia Giannotta; Giacomo Emmi; Gerardo Di Scala; Florenzo Iannone; Claudia Fabiani; Bruno Frediani; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2020-03-31       Impact factor: 4.711

7.  DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists.

Authors:  Federico Navarro-Sarabia; Dolores Ruiz-Montesinos; Blanca Hernandez; Victoria Navarro-Compán; Sara Marsal; Mireia Barcelo; Eva Perez-Pampín; Juan J Gómez-Reino
Journal:  BMC Musculoskelet Disord       Date:  2009-07-23       Impact factor: 2.362

8.  Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.

Authors:  Désirée M van der Heijde; Dennis A Revicki; Katherine L Gooch; Robert L Wong; Hartmut Kupper; Neesha Harnam; Chris Thompson; Joachim Sieper
Journal:  Arthritis Res Ther       Date:  2009-08-17       Impact factor: 5.156

9.  Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study.

Authors:  Fabrizio Cantini; Laura Niccoli; Emanuele Cassarà; Olga Kaloudi; Carlotta Nannini
Journal:  Biologics       Date:  2013-01-04

10.  Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.

Authors:  Adrian Ciurea; Pascale Exer; Ulrich Weber; Giorgio Tamborrini; Beate Steininger; Rudolf O Kissling; Jürg Bernhard; Almut Scherer
Journal:  Arthritis Res Ther       Date:  2016-03-22       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.